Nature Search

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies

Understanding the human antibody response to influenza A virus strains is important for vaccine development. Here, Creanga et al. generate a panel of 55 replication-deficient reporter viruses representing diversity of human H1N1 and H3N2, and pandemic subtypes and characterize the neutralization profile of 24 antibodies and polyclonal sera.

Adrian Creanga
Rebecca A. Gillespie
Masaru Kanekiyo
ResearchOpen Access19 Mar 2021
Nature Communications

Volume: 12, P: 1-12
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

Vaccines against the WA1 SARS-CoV2 strain confer protection against other variants. However, the mechanisms underlying cross-protection are not fully understood. Here, the authors develop a method for rapid analysis of single B cells from patient samples and show that infection with a variant elicits convergent, public B cell responses to other variants.

Noemia S. Lima
Maryam Musayev
Daniel C. Douek
ResearchOpen Access14 Dec 2022
Nature Communications

Volume: 13, P: 1-14
Harnessing low dimensionality to visualize the antibody–virus landscape for influenza

A framework is presented to extrapolate the range of behaviors for influenza antibodies. Using this basis set of behaviors, the collective action of multiple antibodies can be teased apart to describe the individual antibodies within.

Tal Einav
Adrian Creanga
Masaru Kanekiyo
ResearchOpen Access30 Dec 2022
Nature Computational Science

Volume: 3, P: 164-173
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Masaru Kanekiyo
M. Gordon Joyce
Barney S. Graham
Amendments and Corrections12 Apr 2019
Nature Immunology

Volume: 20, P: 765
Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies

Monoclonal antibodies targeting the conserved neuraminidase catalytic site mimic sialic acid and use coordinated water molecules to inhibit diverse influenza A and B viruses, including H5N1, providing broad prophylactic protection in mice.

Julia Lederhofer
Andrew J. Borst
Masaru Kanekiyo
ResearchOpen Access01 Aug 2025
Nature Communications

Volume: 16, P: 1-15
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses

The authors describe the isolation and characterization of broadly cross-neutralizing monoclonal antibodies (mAbs) against diverse H5Nx viruses from individuals who received a monovalent H5N1 vaccine 15 years ago. They identify five mAbs that potently neutralized the majority of H5 clades and protected against lethal 2.3.4.4b H5N1 infection in mice.

Alexandra A. Abu-Shmais
Gray Freeman
Sarah F. Andrews
ResearchOpen Access14 Oct 2025
Nature Microbiology

Volume: 10, P: 2903-2918
A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

A bulky residue in the stem domain of the influenza virus H2 hemagglutinin appears pivotal in eliciting broadly cross-reactive antibodies capable of recognizing diverse group 1 influenza subtypes and is informative for universal influenza vaccine development.

Sarah F. Andrews
Julie E. Raab
Adrian B. McDermott
Research03 Feb 2022
Nature Medicine

Volume: 28, P: 373-382
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

First-in-human trial of a self-assembling, ferritin nanoparticle-based influenza vaccine shows evidence that this new platform can elicit neutralizing and cross-reactive antibodies and has potential for further vaccine development.

Katherine V. Houser
Grace L. Chen
Colin Tran
Research03 Feb 2022
Nature Medicine

Volume: 28, P: 383-391
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Antigenic variation of influenza A viruses necessitates the annual reformulation of vaccines. Kanekiyo et al. develop a mosaic nanoparticle vaccine against influenza virus that is able to elicit neutralizing antibodies that span nearly 100 years of variation of influenza A virus.

Masaru Kanekiyo
M. Gordon Joyce
Barney S. Graham
Research11 Feb 2019
Nature Immunology

Volume: 20, P: 362-372
Prevalence of off-target effects in Drosophila RNA interference screens

The use of long double-stranded RNAs (dsRNAs) in Drosophila, where Dicer-mediated processing produces small RNAs inside cells, has been thought to reduce the probability of 'off-target effects' (OTEs). However, this study shows that OTEs mediated by short homology stretches within long dsRNAs are prevalent in Drosophila.

Yong Ma
Adrian Creanga
Philip A. Beachy
Research10 Sept 2006
Nature

Volume: 443, P: 359-363
Quadrivalent influenza nanoparticle vaccines induce broad protection

A nanoparticle influenza vaccine candidate is shown to induce broad cross-reactive antibody responses in animal models.

Seyhan Boyoglu-Barnum
Daniel Ellis
Masaru Kanekiyo
Research24 Mar 2021
Nature

Volume: 592, P: 623-628
Structure-based design of stabilized recombinant influenza neuraminidase tetramers

Influenza virus neuraminidase (NA) is a drug target and a potential vaccine antigen. Here, the authors provide a detailed analysis of the conformational stability of NA, and show how expression and stability of recombinant NA antigens can be strengthened through structure-based design.

Daniel Ellis
Julia Lederhofer
Masaru Kanekiyo
ResearchOpen Access05 Apr 2022
Nature Communications

Volume: 13, P: 1-16
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

The beta variant (B.1.351) is to date the most resistant to neutralization of the SARS-CoV-2 variants. Using nonhuman primates, Seder and colleagues demonstrate that double vaccination with a high dose of the lipid nanoparticle vaccine mRNA-1273 protects against infection with the beta variant.

Kizzmekia S. Corbett
Anne P. Werner
Robert A. Seder
Research20 Aug 2021
Nature Immunology

Volume: 22, P: 1306-1315
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Joseph P. Casazza
Amelia R. Hofstetter
Rajoshi Chaudhuri
ResearchOpen Access17 Sept 2024
npj Vaccines

Volume: 9, P: 1-10

Search

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

Harnessing low dimensionality to visualize the antibody–virus landscape for influenza

Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies

Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses

A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Prevalence of off-target effects in Drosophila RNA interference screens

Quadrivalent influenza nanoparticle vaccines induce broad protection

Structure-based design of stabilized recombinant influenza neuraminidase tetramers

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Search

Quick links

Search

Filter By:

Search

Quick links